| 郭 智,刘晓东,刘玄勇,郑珊珊,陈丽萍,陈丽娜,陈惠仁.EPOCH-L方案治疗复发难治性T细胞淋巴瘤的临床研究[J].,2019,19(19):3694-3698 |
| EPOCH-L方案治疗复发难治性T细胞淋巴瘤的临床研究 |
| Clinical Research on EPOCH-L Regimen in the Treatment of Relapse and Refractory T Cell Lymphoma |
| 投稿时间：2019-01-27 修订日期：2019-02-24 |
| DOI：10.13241/j.cnki.pmb.2019.19.022 |
| 中文关键词: EPOCH-L方案 复发难治性 T细胞淋巴瘤 化学治疗 |
| 英文关键词: EPOCH-L regimen Relapsed or refractory T cell lymphoma Chemotherapy |
| 基金项目:深圳市卫生系统临床研究类科研项目(SZLY2018003) |
|
| 摘要点击次数: 869 |
| 全文下载次数: 732 |
| 中文摘要: |
| 摘要 目的：探讨EPOCH-L方案治疗复发难治性T细胞淋巴瘤的疗效及安全性。方法：回顾性分析解放军某医院2012年1月至2017年1月收治的12例复发难治性T细胞淋巴瘤患者的临床资料，均采用EPOCH-L方案化疗(依托泊苷50 mg/m2 第1～4天、吡柔比星10 mg/m2 第1～4天、长春地辛1 mg/d 第1～4天、环磷酰胺750 mg/m2 第5天、泼尼龙60 mg/m2 第1～5天、培门冬酶2500 iu/m2 第6天)3～6个周期，并随机选取同期进行异基因造血干细胞移植治疗的12例复发难治性T细胞淋巴瘤患者为对照组，比较两组的临床疗效及不良反应的发生情况。结果：随访至2018年1月，EPOCH-L方案组患者取得完全缓解4例(33.3%)，部分缓解4例(33.3%)，总有效率为66.7%，中位生存期为23.7(7～65)个月，随访期间总生存率为25%；对照组患者中位生存期为9.2(3～60)个月，无病生存率为41.7%，总体生存时间分布差异无统计学意义(P=0.683)。实验组没有患者死于化疗合并症(0.0%)，对照组4例死于移植合并症(33.3%)，差异有统计学意义(P=0.028)。结论：EPOCH-L方案治疗复发难治性T细胞淋巴瘤的临床效果与异基因造血干细胞移植治疗相当，且安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: The study was aimed to explore the effect and safety of EPOCH-L regimen for the patients with relapsed or refractory T cell lymphoma. Methods: 12 cases of patients with relapsed or refractory T cell lymphoma treated with EPOCH-L regimen from January 2012 to January 2017 of PLA hospital were selected: VP-16 50 mg/m2 d1～4, ADM 10 mg/m2 d1～4, VDS 1 mg/d d1～4, CTX 750 mg/m2 d5, Pred 60 mg/m2 d1～5, PEG-Asp 2500 iu/m2 d6. a total of 3 to 6 cycles of chemotherapy was performed. Another 12 cases after allogeneic hematopoietic stem cell transplantation were randomly selected as the control group, the clinical effect and incidence of complications were compared between two groups. Results: Followed up to January 2018, the response rate of experimental group was 66.7%, including 4 cases of complete remission(33.3%) and 4 cases of partial remission (33.3%), the median survival time was 23.7 (7～65) months and the overall survival rate during follow-up was 25%. The median survival time was 9.2 (3～60) months and the overall survival rate was 41.7% in the control group. While there was no significant difference in the overall survival time distribution (P=0.683). No patients died of chemotherapy complications (0.0%) in the experimental group, 4 patients died of transplantation complications (33.3%) in the control group(P=0.028). Conclusion: EPOCH-L regimen is effective and safe for the patients with relapse and refractory T cell lymphoma and the efficacy was equal to allogeneic hematopoietic stem cell transplantation. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
